Physician profile
Nathan J Reed
NPI 1538380993
$12,582.89
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $146 · 2021: $35.65 · 2022: $1,012 · 2023: $8,171 · 2024: $3,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $860 · Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,100.00 |
| Travel and Lodging | $859.88 |
| Food and Beverage | $254.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $12,218.33 | 2019-2024 | Gallant, Allure, Accent |
| Amarin Pharma, INC. | $106.50 | 2020 | |
| Medtronic, INC. | $61.23 | 2021-2022 | |
| Irhythm Technologies, INC. | $37.86 | 2023 | Zio Xt Patch |
| Cardinal Health 200 LLC | $24.13 | 2021 | |
| Edwards Lifesciences Corporation | $19.55 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $19.43 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.00 | 2022 | |
| Medtronic Vascular, INC. | $15.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.13 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.53 | 2020 | |
| Amgen INC. | $11.64 | 2019 | |
| Novo Nordisk INC | $11.21 | 2019 | |
| Pfizer INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.